Solitor 5

Symptomatic treatment of urge incontinence &/or increased urinary frequency & urgency in patients w/ overactive bladder syndrome.

Adult including elderly 5 mg once daily, may be increased to 10 mg once daily if needed. Patient w/ severe renal impairment (CrCl ≤30 mL/min) Max: 5 mg once daily. Patient w/ moderate hepatic impairment (Child-Pugh score 7-9) Max: 5 mg once daily. Concomitant use w/ ketoconazole or other potent CYP3A4 inhibitor eg, ritonavir, nelfinavir, itraconazole Limit max dose to 5 mg.

May be taken with or without food: Swallow whole w/ liqd.

Hypersensitivity. Patients w/ urinary or gastric retention, & uncontrolled narrow-angle glaucoma.

Discontinue use & take appropriate therapy &/or measures if anaphylactic reactions develop; angioedema occurs. Assess other causes of frequent urination (heart failure or renal disease) before treatment. Use w/ caution in patients w/ clinically significant bladder outflow obstruction at risk of urinary retention; GI obstructive disorders & decreased GI motility; reduced renal & hepatic function; hiatus hernia/gastro-esophageal reflux &/or who are concurrently taking medicinal products (eg, bisphosphonates) that can cause or exacerbate esophagitis; autonomic neuropathy; myasthenia gravis. Reports of QT prolongation & torsade de pointes in patients w/ risk factors eg, preexisting long QT syndrome & hypokalemia. May cause blurred vision &, uncommonly, somnolence & fatigue which may negatively affect ability to drive & use machines. Use in pregnancy only if potential benefit justifies potential fetal risk. Not to be administered during nursing. Not to be used in childn.

Dry mouth, nausea. Blurred vision; constipation, dyspepsia, abdominal pain.

Increased AUC w/ ketoconazole (potent CYP3A4 inhibitor).

Drugs for Bladder & Prostate Disorders

G04BD08 - solifenacin ; Belongs to the class of urinary antispasmodics.

Rx